DS23 Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma

Katie O’Connell,Jacob Thomas,Fadi Murad,Guru Sonpavde,Matthew Mossanen,Timothy Clinton,Antonio Ji- Xu,Phillippe Spiess,Anthony Rossi,Chrysalyne Schmults

DOI: https://doi.org/10.1093/bjd/ljae090.218

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Survivorship overlap exists among patients classified according to the American Joint Committee on Cancer (AJCC) 8th edition tumour (T) staging system for penile squamous cell carcinoma (PSCC). At present, the AJCC 8th edition guidelines for PSCC stratify T1 tumours by the presence or absence of perineural invasion (PNI) and lymphovascular invasion, and the degree of differentiation. T2 and T3 tumours are stratified based on the anatomical depth of invasion into the corporal structures, with T4 tumours invading into the scrotum, prostate or pubic bone. This study evaluates the current performance of PSCC AJCC T staging and compares it to an alternative. Different combinations of tumour risk factors were evaluated in terms of distinctiveness (prognostic groupings without overlapping confidence intervals) to determine a new system with the best risk stratification. These characteristics have been set forth by the AJCC to describe the ideal staging system. An alternative staging system was developed from a previously published cohort of 265 patients with PSCC. Tumours were staged via the alternative and AJCC T staging systems. Predictions of metastasis and disease-specific death (DSD) were compared. The alternative and AJCC systems were compared regarding distinctiveness, homogeneity and monotonicity. Three independent predictors of poor outcomes were included in the alternative PSCC T staging system: PNI, poor differentiation, and invasion into corporal structures. In the alternative system, T1 represents 0 risk factors (RF), T2 is 1 RF, T3 is 2 RF, and T4 is 3 RF. The alternative system was superior to AJCC staging in detecting tumours at risk for metastasis (C-statistic: alternative 67% vs. AJCC 63%) and DSD (C-statistic: alternative 74% vs. AJCC 72%). Homogeneity and monotonicity were similar. For alternative T1 disease, the 5-year cumulative incidence of metastasis was 9% and risk of death 5%. The risk of metastasis climbed to 24%, 42% and 74% for alternative T2, T3 and T4 cases, respectively, and 21%, 33% and 60% for DSD. The alternative PSCC T staging system appears to have superior distinctiveness. External validation of the alternative staging system against the AJCC stage should be undertaken. Alternative T1 N0 disease may benefit from nodal staging given the 9% risk of metastasis. Alternative T2/T3/T4 N0 PSCC carries a significant risk of metastasis and death and merits further study for optimal management.

dermatology